Vaginal Cancer – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 4 PAGES: 41

More Info
									                    Vaginal Cancer – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1923IDB
                                                                                              Publication Date: April 2012




Vaginal Cancer – Pipeline Review, H1 2012                                                     GMDHC1923IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Vaginal Cancer – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
Introduction......................................................................................................................................................................................... 5
    Global Markets Direct Report Coverage ........................................................................................................................................ 5
Vaginal Cancer Overview ................................................................................................................................................................... 6
Therapeutics Development................................................................................................................................................................. 7
    An Overview of Pipeline Products for Vaginal Cancer ................................................................................................................... 7
Vaginal Cancer Therapeutics under Development by Companies ..................................................................................................... 9
Vaginal Cancer Therapeutics under Investigation by Universities/Institutes..................................................................................... 10
Late Stage Products ......................................................................................................................................................................... 11
    Comparative Analysis .................................................................................................................................................................. 11
Mid Clinical Stage Products.............................................................................................................................................................. 12
    Comparative Analysis .................................................................................................................................................................. 12
Early Clinical Stage Products ........................................................................................................................................................... 13
    Comparative Analysis .................................................................................................................................................................. 13
Vaginal Cancer Therapeutics – Products under Development by Companies ................................................................................. 14
Vaginal Cancer Therapeutics – Products under Investigation by Universities/Institutes .................................................................. 15
Companies Involved in Vaginal Cancer Therapeutics Development ................................................................................................ 16
    Merck & Co., Inc. ......................................................................................................................................................................... 16
Vaginal Cancer – Therapeutics Assessment .................................................................................................................................... 17
    Assessment by Monotherapy Products ....................................................................................................................................... 17
    Assessment by Combination Products ........................................................................................................................................ 18
    Assessment by Route of Administration ...................................................................................................................................... 19
    Assessment by Molecule Type .................................................................................................................................................... 21
Drug Profiles..................................................................................................................................................................................... 23
    V503 - Drug Profile ...................................................................................................................................................................... 23
         Product Description................................................................................................................................................................. 23
         Mechanism of Action ............................................................................................................................................................... 23
         R&D Progress ......................................................................................................................................................................... 23
    Vinorelbine + Paclitaxel + Radiation Therapy - Drug Profile ........................................................................................................ 24
         Product Description................................................................................................................................................................. 24
         Mechanism of Action ............................................................................................................................................................... 24
         R&D Progress ......................................................................................................................................................................... 24
    Avastin + Radiation Therapy - Drug Profile ................................................................................................................................. 26
         Product Description................................................................................................................................................................. 26
         Mechanism of Action ............................................................................................................................................................... 26
         R&D Progress ......................................................................................................................................................................... 26
    Docetaxel - Drug Profile .............................................................................................................................................................. 27
         Product Description................................................................................................................................................................. 27
         Mechanism of Action ............................................................................................................................................................... 27
         R&D Progress ......................................................................................................................................................................... 27



Vaginal Cancer – Pipeline Review, H1 2012                                                                                                          GMDHC1923IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Vaginal Cancer – Pipeline Review, H1 2012




    Therapeutic allogeneic Lymphocytes + Cyclosporine + Fludarabine Phosphate + Mycophenolate Mofetil + Stem Cell
    Transplantation + Radiation Therapy - Drug Profile .................................................................................................................... 28
         Product Description................................................................................................................................................................. 28
         Mechanism of Action ............................................................................................................................................................... 28
         R&D Progress ......................................................................................................................................................................... 29
    Triapine + Cisplatin + Radiation Therapy - Drug Profile .............................................................................................................. 30
         Product Description.............................................................................
								
To top